Endothelial PAS domain-containing protein 1 confers TKI-resistance by mediating EGFR and MET pathways in non-small cell lung cancer cells

References

• Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clini 2013; 63:11–30; PMID:23335087; http://dx.doi.org/10.3322/caac.21166
   PubMed Web of Science ®Google Scholar
• Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clini 2011; 61:69–90; PMID:21296855.
   PubMed Web of Science ®Google Scholar
• Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350:2129–39; PMID:15118073; http://dx.doi.org/10.1056/NEJMoa040938.
   PubMed Web of Science ®Google Scholar
• Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304:1497–500; PMID:15118125; http://dx.doi.org/10.1126/science.1099314.
   PubMed Web of Science ®Google Scholar
• Janne PA, Engelman JA, Johnson BE. Epidermal growth factor receptor mutations in non-small-cell lung cancer: implications for treatment and tumor biology. J Clini Oncol 2005; 23:3227–34; PMID:15886310; http://dx.doi.org/10.1200/JCO.2005.09.985.
   PubMed Web of Science ®Google Scholar
• Soria JC, Mok TS, Cappuzzo F, Janne PA. EGFR-mutated oncogene-addicted non-small cell lung cancer: current trends and future prospects. Cancer Treat Rev 2012; 38:416–30; PMID:22119437; http://dx.doi.org/10.1016/j.ctrv.2011.10.003.
   PubMed Web of Science ®Google Scholar
• Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 2005; 5:341–54; PMID:15864276; http://dx.doi.org/10.1038/nrc1609.
   PubMed Web of Science ®Google Scholar
• Pao W, Miller VA. Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions. J Clini Oncol 2005; 23:2556–68; PMID:15767641; http://dx.doi.org/10.1200/JCO.2005.07.799.
   PubMed Web of Science ®Google Scholar
• Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, Campos D, Maoleekoonpiroj S, Smylie M, Martins R, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005; 353:123–32; PMID:16014882; http://dx.doi.org/10.1056/NEJMoa050753.
   PubMed Web of Science ®Google Scholar
• Kris MG, Natale RB, Herbst RS, Lynch TJ, Jr., Prager D, Belani CP, Schiller JH, Kelly K, Spiridonidis H, Sandler A, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. Jama 2003; 290:2149–58; PMID:14570950; http://dx.doi.org/10.1001/jama.290.16.2149.
   PubMed Web of Science ®Google Scholar
• Thatcher N, Chang A, Parikh P, Rodrigues Pereira J, Ciuleanu T, von Pawel J, Thongprasert S, Tan EH, Pemberton K, Archer V, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005; 366:1527–37; PMID:16257339; http://dx.doi.org/10.1016/S0140-6736(05)67625-8.
   PubMed Web of Science ®Google Scholar
• Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, Zakowski MF, Kris MG, Varmus H. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005; 2:e73; PMID:15737014; http://dx.doi.org/10.1371/journal.pmed.0020073.
   PubMed Web of Science ®Google Scholar
• Kwak EL, Sordella R, Bell DW, Godin-Heymann N, Okimoto RA, Brannigan BW, Harris PL, Driscoll DR, Fidias P, Lynch TJ, et al. Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc Natl Acad Sci U S A 2005; 102:7665–70; PMID:15897464; http://dx.doi.org/10.1073/pnas.0502860102.
   PubMed Web of Science ®Google Scholar
• Kobayashi S, Boggon TJ, Dayaram T, Janne PA, Kocher O, Meyerson M, Johnson BE, Eck MJ, Tenen DG, Halmos B. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005; 352:786–92; PMID:15728811; http://dx.doi.org/10.1056/NEJMoa044238.
   PubMed Web of Science ®Google Scholar
• Ponzetto C, Bardelli A, Zhen Z, Maina F, dalla Zonca P, Giordano S, Graziani A, Panayotou G, Comoglio PM. A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family. Cell 1994; 77:261–71; PMID:7513258; http://dx.doi.org/10.1016/0092-8674(94)90318-2.
   PubMed Web of Science ®Google Scholar
• Sipeki S, Bander E, Buday L, Farkas G, Bacsy E, Ways DK, Faragó A. Phosphatidylinositol 3-kinase contributes to Erk1/Erk2 MAP kinase activation associated with hepatocyte growth factor-induced cell scattering. Cell Signal 1999; 11:885–90; PMID:10659996; http://dx.doi.org/10.1016/S0898-6568(99)00060-1.
   PubMed Web of Science ®Google Scholar
• Qiao H, Hung W, Tremblay E, Wojcik J, Gui J, Ho J, Klassen J, Campling B, Elliott B. Constitutive activation of met kinase in non-small-cell lung carcinomas correlates with anchorage-independent cell survival. J Cell Biochem 2002; 86:665–77; PMID:12210733; http://dx.doi.org/10.1002/jcb.10239.
   PubMed Web of Science ®Google Scholar
• Bredin CG, Liu Z, Klominek J. Growth factor-enhanced expression and activity of matrix metalloproteases in human non-small cell lung cancer cell lines. Anticancer Res 2003; 23:4877–84; PMID:14981939.
   PubMed Web of Science ®Google Scholar
• Jo M, Stolz DB, Esplen JE, Dorko K, Michalopoulos GK, Strom SC. Cross-talk between epidermal growth factor receptor and c-Met signal pathways in transformed cells. J Biol Chem 2000; 275:8806–11; PMID:10722725; http://dx.doi.org/10.1074/jbc.275.12.8806.
   PubMed Web of Science ®Google Scholar
• Huang PH, Mukasa A, Bonavia R, Flynn RA, Brewer ZE, Cavenee WK, Furnari FB, White FM. Quantitative analysis of EGFRvIII cellular signaling networks reveals a combinatorial therapeutic strategy for glioblastoma. Proc Natl Acad Sci U S A 2007; 104:12867–72; PMID:17646646; http://dx.doi.org/10.1073/pnas.0705158104.
   PubMed Web of Science ®Google Scholar
• Guo A, Villen J, Kornhauser J, Lee KA, Stokes MP, Rikova K, Possemato A, Nardone J, Innocenti G, Wetzel R, et al. Signaling networks assembled by oncogenic EGFR and c-Met. Proc Natl Acad Sci U S A 2008; 105:692–7; PMID:18180459; http://dx.doi.org/10.1073/pnas.0707270105.
   PubMed Web of Science ®Google Scholar
• Bergstrom JD, Westermark B, Heldin NE. Epidermal growth factor receptor signaling activates met in human anaplastic thyroid carcinoma cells. Experimental cell research 2000; 259:293–9; PMID:10942601; http://dx.doi.org/10.1006/excr.2000.4967.
   PubMed Web of Science ®Google Scholar
• Pai R, Nakamura T, Moon WS, Tarnawski AS. Prostaglandins promote colon cancer cell invasion; signaling by cross-talk between two distinct growth factor receptors. FASEB J 2003; 17:1640–7; PMID:12958170; http://dx.doi.org/10.1096/fj.02-1011com.
   PubMed Web of Science ®Google Scholar
• Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, Lindeman N, Gale CM, Zhao X, Christensen J, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007; 316:1039–43; PMID:17463250; http://dx.doi.org/10.1126/science.1141478.
   PubMed Web of Science ®Google Scholar
• Xu L, Nilsson MB, Saintigny P, Cascone T, Herynk MH, Du Z, Nikolinakos PG, Yang Y, Prudkin L, Liu D, et al. Epidermal growth factor receptor regulates MET levels and invasiveness through hypoxia-inducible factor-1alpha in non-small cell lung cancer cells. Oncogene 2010; 29:2616–27; PMID:20154724; http://dx.doi.org/10.1038/onc.2010.16.
   PubMed Web of Science ®Google Scholar
• Tian H, McKnight SL, Russell DW. Endothelial PAS domain protein 1 (EPAS1), a transcription factor selectively expressed in endothelial cells. Genes Dev 1997; 11:72–82; PMID:9000051; http://dx.doi.org/10.1101/gad.11.1.72.
   PubMed Web of Science ®Google Scholar
• Smyth EC, Sclafani F, Cunningham D. Emerging molecular targets in oncology: clinical potential of MET/hepatocyte growth-factor inhibitors. OncoTargets and therapy 2014; 7:1001–14; PMID:24959087; http://dx.doi.org/10.2147/OTT.S44941.
   PubMed Web of Science ®Google Scholar
• Burgess AW, Cho HS, Eigenbrot C, Ferguson KM, Garrett TP, Leahy DJ, Lemmon MA, Sliwkowski MX, Ward CW, Yokoyama S. An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors. Mol Cell 2003; 12:541–52; PMID:14527402; http://dx.doi.org/10.1016/S1097-2765(03)00350-2.
   PubMed Web of Science ®Google Scholar
• Tian H, Hammer RE, Matsumoto AM, Russell DW, McKnight SL. The hypoxia-responsive transcription factor EPAS1 is essential for catecholamine homeostasis and protection against heart failure during embryonic development. Genes Dev 1998; 12:3320–4; PMID:9808618; http://dx.doi.org/10.1101/gad.12.21.3320.
   PubMed Web of Science ®Google Scholar
• Gruber M, Mathew LK, Runge AC, Garcia JA, Simon MC. EPAS1 Is Required for Spermatogenesis in the Postnatal Mouse Testis. Biol Reprod 2010; 82:1227–36; PMID:20181618; http://dx.doi.org/10.1095/biolreprod.109.079202.
   PubMed Web of Science ®Google Scholar
• Troiani T, Martinelli E, Napolitano S, Vitagliano D, Ciuffreda LP, Costantino S, Morgillo F, Capasso A, Sforza V, Nappi A, et al. Increased TGF-α as a mechanism of acquired resistance to the anti-EGFR inhibitor cetuximab through EGFR-MET interaction and activation of MET signaling in colon cancer cells. Clini Cancer Res 2013; 19:6751–65; PMID:24122793; http://dx.doi.org/10.1158/1078-0432.CCR-13-0423.
   PubMed Web of Science ®Google Scholar
• Bardelli A, Corso S, Bertotti A, Hobor S, Valtorta E, Siravegna G, Sartore-Bianchi A, Scala E, Cassingena A, Zecchin D, et al. Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer. Cancer Discov 2013; 3:658–73; PMID:23729478; http://dx.doi.org/10.1158/2159-8290.CD-12-0558.
   PubMed Web of Science ®Google Scholar
• Bell DW, Gore I, Okimoto RA, Godin-Heymann N, Sordella R, Mulloy R, Sharma SV, Brannigan BW, Mohapatra G, Settleman J, et al. Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR. Nature genetics 2005; 37:1315–6; PMID:16258541; http://dx.doi.org/10.1038/ng1671.
   PubMed Web of Science ®Google Scholar
• Toyooka S, Kiura K, Mitsudomi T. EGFR mutation and response of lung cancer to gefitinib. N Engl J Med 2005; 352:2136; author reply; PMID:15901872; http://dx.doi.org/10.1056/NEJM200505193522019.
   PubMed Web of Science ®Google Scholar
• Engelman JA, Mukohara T, Zejnullahu K, Lifshits E, Borras AM, Gale CM, Naumov GN, Yeap BY, Jarrell E, Sun J, et al. Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer. J Clini Invest 2006; 116:2695–706; PMID:16906227; http://dx.doi.org/10.1172/JCI28656.
   PubMed Web of Science ®Google Scholar
• Yun CH, Boggon TJ, Li Y, Woo MS, Greulich H, Meyerson M, Eck MJ. Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity. Cancer Cell 2007; 11:217–27; PMID:17349580; http://dx.doi.org/10.1016/j.ccr.2006.12.017.
   PubMed Web of Science ®Google Scholar
• Stamos J, Sliwkowski MX, Eigenbrot C. Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor. J Biol Chem 2002; 277:46265–72.; PMID:12196540; http://dx.doi.org/10.1074/jbc.M207135200.
   PubMed Web of Science ®Google Scholar
• Puri N, Salgia R. Synergism of EGFR and c-Met pathways, cross-talk and inhibition, in non-small cell lung cancer. J Carcinog 2008; 7:9; PMID:19240370; http://dx.doi.org/10.4103/1477-3163.44372.
   PubMedGoogle Scholar
• Nakagawa T, Takeuchi S, Yamada T, Nanjo S, Ishikawa D, Sano T, Kita K, Nakamura T, Matsumoto K, Suda K, et al. Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer. Mol Cancer Ther 2012; 11:2149–57; PMID:22844075; http://dx.doi.org/10.1158/1535-7163.MCT-12-0195.
   PubMed Web of Science ®Google Scholar
• Xu L, Kikuchi E, Xu C, Ebi H, Ercan D, Cheng KA, Padera R, Engelman JA, Jänne PA, Shapiro GI, et al. Combined EGFR/MET or EGFR/HSP90 inhibition is effective in the treatment of lung cancers codriven by mutant EGFR containing T790M and MET. Cancer Res 2012; 72:3302–11; PMID:22552292; http://dx.doi.org/10.1158/0008-5472.CAN-11-3720.
   PubMed Web of Science ®Google Scholar
• Tracy S, Mukohara T, Hansen M, Meyerson M, Johnson BE, Janne PA. Gefitinib induces apoptosis in the EGFRL858R non-small-cell lung cancer cell line H3255. Cancer Res 2004; 64:7241–4; PMID:15492241; http://dx.doi.org/10.1158/0008-5472.CAN-04-1905.
   PubMed Web of Science ®Google Scholar
• Franken NA, Rodermond HM, Stap J, Haveman J, van Bree C. Clonogenic assay of cells in vitro. Nature Protoc 2006; 1:2315–9; PMID:17406473; http://dx.doi.org/10.1038/nprot.2006.339.
   PubMed Web of Science ®Google Scholar